Compounds, compositions, and methods for increasing CFTR activity

1. A compound having the Formula (Ia) or (Ib):

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

R 2a is hydrogen or fluoro;

R 3 is hydrogen or fluoro;

A is an optionally substituted 5- or 6-membered heteroaryl;

each R e is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and

q is 1 or 2.

2. The compound of claim 1 , wherein R 3 is hydrogen.

3. The compound of claim 1 , wherein R 2a is hydrogen.

4. The compound of claim 1 , wherein R 2a is fluoro.

5. The compound of claim 1 , wherein A is selected from the group consisting of furanyl, pyridinyl, pyrazinyl, pyridizanyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, triazolyl, thiazolyl, oxadiazolyl, thienyl, and benzimidazolyl, each optionally substituted.

6. The compound of claim 5 , wherein A is an optionally substituted imidazolyl or optionally substituted pyrazolyl.

7. The compound of claim 1 , wherein A is a 5- or 6-membered heteroaryl optionally substituted with one to four R 6 , wherein:

each R 6 is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, C(O)OR c , C(O)R c , C(O)C(O)R c and S(O) n R c ;

each R c is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and

each n is independently 0, 1 or 2.

8. The compound of claim 1 , wherein A is a 5- or 6-membered heteroaryl substituted with one to four R 7 groups, wherein:

each R 7 is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, halo, OR c , NR d R d , S(O) n R c , C(O)OR c , NO 2 , CN and C(O)R c , and wherein said 5- or 6-membered heteroaryl is optionally further substituted;

each R c is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

each R d is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C 10 alkoxy, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; or two geminal R d groups are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic or an optionally substituted heteroaryl; and

each n is independently 0, 1 or 2.

9. The compound of claim 8 , wherein at least one R 7 is selected from the group consisting of optionally substituted C 1 -C 10 alkyl, optionally substituted C 3 -C 12 cycloalkyl, and OR c , wherein R c is an optionally substituted C 1 -C 10 alkyl.

10. The compound of claim 8 , wherein at least one R 7 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl, wherein the C 1 -C 4 alkyl and C 3 -C 7 cycloalkyl are each optionally substituted with one or more groups selected from OR f , NR g R g , and SR h ,

wherein each of R f and R h is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and

R g is selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 1 -C 10 alkoxy, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; or alternatively, two geminal R g groups are taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic or an optionally substituted heteroaryl.

11. The compound of claim 8 , wherein at least one of R 7 is C 1 -C 4 alkyl optionally substituted with OR f , wherein R f is selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, and optionally substituted C 3 -C 12 cycloalkyl.

12. The compound of claim 11 , wherein R f is hydrogen.

13. The compound of claim 1 , wherein the R 7 is a C 1 -C 4 alkyl substituted with one or more fluoro, and optionally further substituted.

14. The compound of claim 1 , wherein A is a 5- or 6-membered heteroaryl substituted with at least one R 8 group having the structure:

wherein R 6a , R 6b , R 6c , and R 6d are each independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl and optionally substituted C 3 -C 12 cycloalkyl; or alternatively, a geminal R 6a and R 6b , or a geminal R 6c and R 6d , can each independently be taken together with the carbon atoms to which they are attached to form an optionally substituted C 3 -C 12 cycloalkyl or an optionally substituted heterocyclic;

Y is O, S or NR i ;

t and r are each independently 0, 1, 2 or 3;

R 9 is selected from the group consisting of optionally substituted C 1 -C 10 alkyl and optionally substituted C 3 -C 12 cycloalkyl, optionally substituted heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl; and

R i is selected from the group consisting of hydrogen, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

and wherein the 5- or 6-membered heteroaryl is optionally further substituted.

15. The compound of claim 1 , wherein R e is hydrogen or optionally substituted C 1 -C 4 alkyl.

16. The compound of claim 1 , wherein q is 1.

17. The compound of claim 1 , wherein q is 2.

18. The compound of claim 1 , wherein the compound is selected from the group consisting of:

and a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier or excipient.

20. A compound represented by:

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

pp is 1, 2, or 3;

R 11 is independently selected for each occurrence from the group consisting of hydrogen, halogen, C 1-4 alkyl (optionally substituted by one, two or three halogens);

R 31 is selected from the group consisting of hydrogen, halogen, and C 1-4 alkyl;

L 1 is selected from the group consisting of C 2-3 alkylene-NR hh —S(O) w — and —C 1-3 alkylene-S(O) w —NR hh —, wherein w is 0, 1, or 2, and L 1 may be optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxyl, C 1-3 alkyl (optionally substituted by one, two or three substituents each selected independently from R ff );

R 44 is selected from the group consisting of heterocycle and a 5-6 membered monocyclic heteroaryl having one, two or three heteroatoms each selected from O, N, and S; wherein the heterocycle and the heteroaryl may be each optionally substituted by one or two substituents each selected independently from the group consisting of halogen, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-7 cycloalkyl, wherein each of C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-7 cycloalkyl may be optionally substituted by one, two or three substituents each independently selected from R gg ;

R gg is selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl, C(O)OH, —C(O)OC 1-6 alkyl, —O—C 3-6 cycloalkyl, —O-heterocycle, —O-heteroaryl, —O-phenyl, —NR′R″, —NR′—S(O) w —C 1-3 alkyl, S(O) w —NR′R″, and —S(O) w —C 1-3 alkyl wherein w is 0, 1, or 2;

R ff is selected for each occurrence from group consisting of halogen, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkenyl, C 3-6 cycloalkyl, —NR′R″, —NR′—S(O) w —C 1-3 alkyl, S(O) w —NR′R″, and —S(O) w —C 1-3 alkyl, where w is 0, 1, or 2, wherein C 1-4 alkyl, C 1-4 alkyoxy, C 2-4 alkenyl and C 3-6 cycloalkyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, —NR′R″, —NR′—S(O) w —C 1-3 alkyl, S(O) w —NR′R″, and —S(O) w —C 1-3 alkyl;

R hh is selected for each occurrence from the group consisting of H, C 1-6 alkyl and C 3-6 cycloalkyl; and

R′ and R″ are each independently selected for each occurrence from H and C 1-4 alkyl or taken together with the nitrogen to which they are attached form a heterocyclic ring.

21. The compound of claim 20 , wherein R 44 is selected from the group consisting of:

wherein X 2 independently for each occurrence is selected from the group consisting of O, S or NR hh ; and each R 66 , R 77 and R 88 is independently selected for each occurrence from H, halogen, hydroxyl, and C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted by one, two or three substituents each independently selected from the group consisting of hydroxyl or C 1-6 alkoxy.

22. The compound of claim 20 , wherein R 44 is 5 or 6 membered heteroaryl having one or two nitrogens, and wherein R 44 is substituted on a free carbon by a substituent selected from the group consisting of: a methyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy, ethyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy, propyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy), isopropyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy, n-butyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy, t-butyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy, s-butyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy and isobutyl substituted by one, two or three substituents each selected from halogen, hydroxyl, methoxy and ethoxy.

23. The compound of claim 20 , wherein R 11 for each occurrence is H.

24. The compound of claim 20 , wherein R 31 is H.

25. The compound of claim 20 , wherein L 1 is C 2-3 alkylene-NH—S(O) 2 — or —C 1-3 alkylene-S(O) 2 —NH—.

26. A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically acceptable excipient.